Search results for " placebo"

showing 10 items of 19 documents

Specific transfer effects following variable priority dual-task training in older adults

2016

International audience; Purpose: Past divided attention training studies in older adults have suggested that variable priority training (VPT) tends to show larger improvement than fixed priority training (FPT). However, it remains unclear whether VPT leads to larger transfer effects. Methods: In this study, eighty-three older adults aged between 55 and 65 received five 1-hour sessions of VPT, FPT or of an active placebo. VPT and FPT subjects trained on a complex dual-task condition with variable stimulus timings in order to promote more flexible and self-guided strategies with regard to attentional priority devoted to the concurrent tasks. Real-time individualized feedback was provided to e…

Active placeboMalemedicine.medical_specialtyAgingComputer User TrainingTransfertTransfer Psychology[ SCCO.PSYC ] Cognitive science/PsychologyStimulus (physiology)Neuropsychological Tests050105 experimental psychology[ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationDiscrimination PsychologicalDevelopmental NeuroscienceComputer User TrainingmedicineReaction TimeHumans0501 psychology and cognitive sciencesAttentionAgedAnalysis of Variance[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behaviorTeaching[SCCO.NEUR]Cognitive science/Neuroscience05 social sciencesMiddle AgedDivided attentionCognitive trainingVariable priority trainingNeurologyPattern Recognition VisualCognitive trainingDivided attentionOlder adults[SCCO.PSYC]Cognitive science/Psychology[ SCCO.NEUR ] Cognitive science/NeuroscienceFemaleNeurology (clinical)Analysis of varianceIndependent LivingPsychology030217 neurology & neurosurgery
researchProduct

Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for…

2004

BACKGROUND: H 1 -receptor antagonists are considered to be particularly effective in reducing pruritus, and they are therefore recommended as first-line treatment in patients with chronic idiopathic urticaria (CIU). Recently, antileukotriene receptors have been used in patients with CIU, either administered as monotherapy or combined with H 1 -receptor antagonists. OBJECTIVE: We compared the clinical efficacy of 5 mg of desloratadine administered once daily either as monotherapy or combined with a leukotriene antagonist, 10 mg of montelukast daily, and 10 mg of montelukast administered daily as monotherapy for the treatment of patients affected by CIU with placebo. METHODS: One hundred sixt…

AdultCyclopropanesMalemedicine.medical_specialtyHistamine H1 Antagonists Non-SedatingSettore MED/09 - Medicina InternaAdolescentUrticariamedicine.medical_treatmentImmunologyPlacebo-controlled studyRandomized placebo-controlled trial; desloratadine; montelukast; chronic idiopathic urticariaAcetatesSulfidesPlaceboGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineImmunology and AllergyHumansMontelukastAgedDesloratadineLeukotriene E4Leukotriene receptorbusiness.industrydesloratadineRandomized placebo-controlled trialLoratadineMiddle AgedAntileukotrieneTreatment OutcomechemistryAnesthesiachronic idiopathic urticariaChronic DiseasemontelukastQuinolinesLeukotriene AntagonistsFemalebusinessmedicine.drug
researchProduct

Monosodium benzoate hypersensitivity in subjects with persistent rhinitis

2004

Background:  Very few data are available from the literature on whether nonatopic subjects affected by persistent rhinitis may show the appearance of objective symptoms of rhinitis after the ingestion of food additives such as tartrazine (E102), erythrosine (E127), monosodium benzoate (E211), p-hydroxybenzoate (E218), sodium metabisulphite (E223), and monosodium glutamate (E620). It is still unclear whether the ingestion of food additive may cause, as well, a consensual reduction of nasal peak inspiratory flow (NPIFR). Therefore, we used a double-blind placebo-controlled (DBPC) study to evaluate this hypothesis. Patients and methods:  Two hundred and twenty-six consecutive patients (76 male…

AdultHypersensitivity ImmediateMaleAllergymedicine.medical_specialtySettore MED/09 - Medicina InternaAdolescentMonosodium glutamateImmunologyGastroenterologychemistry.chemical_compoundVasomotor RhinitisInternal medicineImmunopathologySodium BenzoatemedicineImmunology and AllergyIngestionHumansMonosodium benzoate; hypersensitivity; persistent rhinitisChildRhinitisbusiness.industryMonosodium benzoatedouble-blind placebo-controlledMiddle Agednasal peak inspiratory flowmedicine.diseasefood additivesRegimenchemistryImmunologyChronic DiseaseEtiologyFood PreservativesFemalehypersensitivityNasal CavitybusinessPulmonary Ventilationpersistent rhinitisTartrazine
researchProduct

Effectiveness of high dose sublingual immunotherapy to induce a stepdown of seasonal asthma: a pilot study

2009

There is ample evidence to support the efficacy of sublingual immunotherapy (SLIT) on allergic rhinitis, while there is less solid data regarding asthma. We evaluated the effects of a high dose birch SLIT on birch-induced rhinitis and asthma in a controlled study.This double-blind, placebo-controlled, randomised, single centre trial on SLIT with birch pollen allergen extract (Stallergenes, Antony, France) included 24 patients presenting severe rhinitis and slight to moderate asthma, 14 actively and 10 placebo treated. SLIT was performed by a pre-coseasonal protocol, and was repeated for 2 years. The study plan included a selection visit, a visit at the start of the first and the second trea…

AdultMalemedicine.medical_specialtyModerate asthmaDouble-Blind Method; Humans; Immunotherapy; Seasons; Adult; Asthma; Placebos; Pilot Projects; Middle Aged; Male; Female; Drug Administration RoutesPilot ProjectsPlacebolaw.inventionPlacebosSeasonal asthmaRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHumansSublingual immunotherapyPilot ProjectPlaceboAsthmabusiness.industryDrug Administration RoutesGeneral MedicineMiddle Agedmedicine.diseaseSlitAsthmaSurgerySingle centreFemaleSeasonsImmunotherapySeasonSLIT asthma allergybusinessHuman
researchProduct

Abdominal Ultrasound Does Not Reveal Significant Alterations in Patients With Nonceliac Wheat Sensitivity

2017

Abstract GOALS: The goal of this study was (A) to evaluate abdominal ultrasound signs in nonceliac wheat sensitivity (NCWS) patients for features useful in diagnosis and (B) to compare these aspects with those of celiac patients to assess whether ultrasound can be useful in the differential diagnosis between NCWS and celiac disease (CD). BACKGROUND: NCWS diagnosis is difficult as no biomarkers of this condition have as yet been identified. In CD ultrasound aspects have been identified that have a good diagnostic accuracy. STUDY: We prospectively recruited 45 NCWS patients (11 males, 34 females; mean age 35.7 y). Three control groups were included: (A) 99 age-matched CD patients; (B) 18 pati…

AdultMalemedicine.medical_specialtyNon-Celiac Wheat sensitivity Celiac Disease Abdominal Ultrasound Seronegative celiac disease Double-blind placebo-controlled challengeSettore MED/09 - Medicina InternaGlutensWheat HypersensitivityGastroenterology030218 nuclear medicine & medical imagingDiagnosis DifferentialIrritable Bowel SyndromeDiet Gluten-FreeYoung Adult03 medical and health sciences0302 clinical medicineDouble-Blind MethodInternal medicineElimination dietAbdomenAscitesmedicineHumansMesenteric lymph nodesProspective StudiesProspective cohort studyIrritable bowel syndromeUltrasonographybusiness.industryUltrasoundGastroenterologyMiddle Agedmedicine.diseaseCeliac Diseasemedicine.anatomical_structureFemale030211 gastroenterology & hepatologyGluten freemedicine.symptomDifferential diagnosisbusiness
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus monteluk…

2004

BACKGROUND: Corticosteroids are considered to be particularly effective in reducing nasal congestion and are therefore recommended as first-line treatment in allergic rhinitis patients with moderate to severe and/or persistent symptoms. OBJECTIVE: We compared the clinical efficacy of fluticasone propionate aqueous nasal spray (FPANS) 200 microg given once daily, administered in mono-therapy or combined therapy with a H1 receptor antagonist (cetirizine, CTZ) or with a leukotriene antagonist (montelukast, MSK), and the combined therapy of CTZ plus MSK in the treatment of patients affected by allergic rhinitis to Parietaria during natural pollen exposure. In addition, we examined the effect of…

CyclopropanesMaleAllergySettore MED/09 - Medicina Internamedicine.medical_treatmentseasonal allergic rhinitisAcetatesGastroenterologyImmunology and AllergyMedicineChildFluticasonepollen seasonRandomized placebo-controlled trialBlood Proteinsrespiratory systemEosinophil Granule ProteinsMiddle AgedCetirizineAnesthesiamontelukastHistamine H1 AntagonistsQuinolineseosinophil cationic proteinDrug Therapy CombinationFemaleeosinophilsmedicine.symptommedicine.drugAdultmedicine.medical_specialtyAdolescentImmunologyNasal congestionSulfidesPlaceboFluticasone propionateDrug Administration ScheduleRibonucleasesDouble-Blind MethodInternal medicineHumansRandomized placebo-controlled trial; fluticasone; cetirizine; montelukast; seasonal allergic rhinitisGlucocorticoidsMontelukastAdministration IntranasalAnalysis of Variancerhinorrheafluticasone propionatebusiness.industrynasal lavageRhinitis Allergic Seasonalmedicine.diseaseCetirizineAndrostadienesParietariaNasal sprayFluticasoneLeukotriene AntagonistsNasal administrationbusinessClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts’ Criteria

2015

Non-Celiac Gluten Sensitivity (NCGS) is a syndrome characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food, in subjects that are not affected by either celiac disease or wheat allergy. Given the lack of a NCGS biomarker, there is the need for standardizing the procedure leading to the diagnosis confirmation. In this paper we report experts' recommendations on how the diagnostic protocol should be performed for the confirmation of NCGS. A full diagnostic procedure should assess the clinical response to the gluten-free diet (GFD) and measure the effect of a gluten challenge after a period of treatment with the GFD. The clinical evaluation i…

Diagnosis; Non-Celiac Gluten SensitivityPediatricsmedicine.medical_specialtySettore MED/09 - Medicina InternaGlutensdiagnosislcsh:TX341-641DiseasePlaceboArticleDiet Gluten-FreeDouble-Blind MethodRating scaleSurveys and QuestionnairesHumansMedicineIntestinal MucosaIrritable bowel syndromedouble-blind placebo-controlled challengechemistry.chemical_classificationirritable bowel syndromeCross-Over StudiesNutrition and Dieteticsbusiness.industrynon-celiac gluten sensitivitygastrointestinal symptom rating scalenutritional and metabolic diseasesmedicine.diseaseGlutenCrossover studySurgerychemistryImmunoglobulin GBiomarker (medicine)businesslcsh:Nutrition. Foods and food supplyBiomarkersFood HypersensitivityWheat allergyFood ScienceDiagnosiNutrients
researchProduct

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension:A Double-Blind Placebo-controlled Clinical Trial

2020

Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.\ud \ud Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy.\ud \ud Methods: In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily. Eligible participants were using approved oral monotherapy for over 30 days before randomization and had a 6-minute-walk dista…

MaleAdministration OralOral treprostinilCritical Care and Intensive Care MedicinePulmonary arterial hypertension[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractcombination therapyoralepoprostenol0302 clinical medicinepulmonary arterial hypertensionmiddle agedClinical endpointdouble-blind methodMESH: Double-Blind MethodFamilial Primary Pulmonary Hypertension030212 general & internal medicinehumansMESH: AgedMESH: Middle AgedEpoprostenol/analogs & derivativesadultHazard ratioMiddle Aged[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesantihypertensive agents3. Good healthagedfemaleMESH: Young Adultoral treprostinilMESH: Administration Oralyoung adultFemalePulmonary Arterial Hypertension/drug therapymedicine.drugAdultPulmonary and Respiratory MedicineMESH: Pulmonary Arterial Hypertensionmedicine.medical_specialtyRandomizationAdolescentclinical study; combination therapy; oral treprostinil; pulmonary arterial hypertension; sequential therapy; administration oral; adolescent; adult; aged; antihypertensive agents; double-blind method; epoprostenol; female; humans; male; middle aged; placebos; pulmonary arterial hypertension; young adultSequential therapyMESH: PlacebosMESH: EpoprostenolLower riskPlaceboadministrationClinical studyYoung Adult03 medical and health sciencesDouble-Blind Method[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmaleInternal medicineplacebosmedicineHumansCombination therapyAdverse effectPlacebos/therapeutic useAgedMESH: AdolescentPulmonary Vascular DiseaseMESH: Antihypertensive AgentsMESH: Humanssequential therapybusiness.industryMESH: AdultOriginal Articlesclinical studyMESH: MaleClinical trial030228 respiratory systemadolescentAntihypertensive Agents/administration & dosagebusinessMESH: FemaleTreprostinil
researchProduct

Mongersen, an oral SMAD7 antisense oligonucleotide, and crohn's disease

2015

Crohn's disease-related inflammation is characterized by reduced activity of the immunosuppressive cytokine transforming growth factor β1 (TGF-β1) due to high levels of SMAD7, an inhibitor of TGF-β1 signaling. Preclinical studies and a phase 1 study have shown that an oral SMAD7 antisense oligonucleotide, mongersen, targets ileal and colonic SMAD7.In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of mongersen for the treatment of persons with active Crohn's disease. Patients were randomly assigned to receive 10, 40, or 160 mg of mongersen or placebo per day for 2 weeks. The primary outcomes were clinical remission at day 15, defined as a Crohn's Disease Activit…

MaleSMAD7 antisense oligonucleotidemedicine.medical_treatmentOligonucleotidesPharmacologyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologylaw.inventionACTIVATIONImmunosuppressive AgentGlucocorticoidRandomized controlled trialCrohn DiseaselawOligonucleotideMedicineYoung adultCrohn's diseaseSettore MED/12 - GastroenterologiabiologyINDUCTIONMedicine (all)Remission InductionGeneral MedicineMiddle AgedCrohn's diseaseCytokineC-Reactive ProteinCombinationDrug Therapy CombinationFemaleDrugImmunosuppressive AgentsCOLITISHumanAdultmedicine.medical_specialtyAdolescentINFLAMMATORY-BOWEL-DISEASE PLACEBO-CONTROLLED TRIAL NECROSIS-FACTOR-ALPHA TGF-BETA-1-MEDIATED SUPPRESSION COLITIS INDUCTION ACTIVATION EFFICACY THERAPY MICEPlaceboSmad7 ProteinDose-Response RelationshipYoung AdultPharmacotherapyDouble-Blind MethodDrug TherapyInternal medicineHumansAntisenseGlucocorticoidsAgedDose-Response Relationship Drugbusiness.industryC-reactive proteinNECROSIS-FACTOR-ALPHAOligonucleotides AntisenseTGF-BETA-1-MEDIATED SUPPRESSIONEFFICACYmedicine.diseaseClinical trialMICEbiology.proteinbusinessAdolescent; Adult; Aged; C-Reactive Protein; Crohn Disease; Dose-Response Relationship Drug; Double-Blind Method; Drug Therapy Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Middle Aged; Oligonucleotides; Oligonucleotides Antisense; Remission Induction; Smad7 Protein; Young Adult; Medicine (all)INFLAMMATORY-BOWEL-DISEASE
researchProduct